Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Assessment Of BRAF V600E Mutation Status By Immunohistochemistry With A Mutation-specific Monoclonal Antibody

D. Capper, M. Preusser, A. Habel, F. Sahm, U. Ackermann, Genevieve Schindler, S. Pusch, G. Mechtersheimer, H. Zentgraf, A. Deimling
Published 2011 · Biology, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Activating mutations of the serine threonine kinase v-RAF murine sarcoma viral oncogene homolog B1 (BRAF) are frequent in benign and malignant human tumors and are emerging as an important biomarker. Over 95% of BRAF mutations are of the V600E type and specific small molecular inhibitors are currently under pre-clinical or clinical investigation. BRAF mutation status is determined by DNA-based methods, most commonly by sequencing. Here we describe the development of a monoclonal BRAF V600E mutation-specific antibody that can differentiate BRAF V600E and wild type protein in routinely processed formalin-fixed and paraffin-embedded tissue. A total of 47 intracerebral melanoma metastases and 21 primary papillary thyroid carcinomas were evaluated by direct sequencing of BRAF and by immunohistochemistry using the BRAF V600E mutation-specific antibody clone VE1. Correlation of VE1 immunohistochemistry and BRAF sequencing revealed a perfect match for both papillary thyroid carcinomas and melanoma metastases. The staining intensity in BRAF V600E mutated tumor samples ranged from weak to strong. The generally homogenous VE1 staining patterns argue against a clonal heterogeneity of the tumors investigated. Caution is essential when only poorly preserved tissue is available for VE1 immunohistochemical analysis or when tissues with only little total BRAF protein are analyzed. Immunohistochemistry using antibody VE1 may substantially facilitate molecular analysis of BRAF V600E status for diagnostic, prognostic, and predictive purposes.
This paper references
10.1038/ng1054
High frequency of BRAF mutations in nevi
P. Pollock (2003)
Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia.
S. Yuen (2002)
10.1097/PAS.0b013e3181e7740d
Application of Mutant IDH1 Antibody to Differentiate Diffuse Glioma From Nonneoplastic Central Nervous System Lesions and Therapy-induced Changes
D. Capper (2010)
Expression and activation of B-Raf kinase isoforms in human and murine leukemia cell lines.
A. Eychène (1995)
10.1111/j.1440-1827.1996.tb03580.x
Feasibility of archival non‐buffered formalin‐fixed and paraffin‐embedded tissues for PCR amplification: An analysis of resected gastric carcinoma
T. Inoue (1996)
10.1038/nature09626
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
R. Nazarian (2010)
10.1200/JCO.2010.28.15_SUPPL.8503
Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors.
R. Kefford (2010)
10.1007/s00401-011-0802-6
Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma
G. Schindler (2011)
10.1056/NEJMoa1002011
Inhibition of mutated, activated BRAF in metastatic melanoma.
K. Flaherty (2010)
10.1093/JNCI/95.8.625
BRAF mutation in papillary thyroid carcinoma.
Yoram Cohen (2003)
10.1038/sj.bjc.6606072
Polyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression
J. Lin (2011)
10.1002/path.2496
Aberrant BRAF splicing as an alternative mechanism for oncogenic B‐Raf activation in thyroid carcinoma
E. Baitei (2009)
10.1002/path.2913
IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours
M. F. Amary (2011)
10.1038/256495a0
Continuous cultures of fused cells secreting antibody of predefined specificity
G. Köhler (1975)
10.1007/s00401-009-0595-z
Monoclonal antibody specific for IDH1 R132H mutation
D. Capper (2009)
10.1016/S1470-2045(10)70130-3
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
W. De Roock (2010)
10.1182/blood-2010-04-279083
Recurrent BRAF mutations in Langerhans cell histiocytosis.
G. Badalian-Very (2010)
10.1016/j.jmoldx.2010.11.005
Detection of KRAS and BRAF mutations in colorectal carcinoma roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotyping.
M. Arcila (2011)
10.1074/jbc.270.40.23381
The Mouse B-raf Gene Encodes Multiple Protein Isoforms with Tissue-specific Expression (*)
J. Barnier (1995)
10.1016/j.leukres.2010.02.014
Detection of isocitrate dehydrogenase 1 mutation R132H in myelodysplastic syndrome by mutation-specific antibody and direct sequencing.
M. Andrulis (2010)
10.1016/j.molonc.2007.12.003
Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site
A. Platz (2008)
10.1043/2010-0664-RAIR.1
Molecular diagnostics of thyroid tumors.
Y. Nikiforov (2011)
High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.
E. Kimura (2003)
10.1007/s11060-011-0587-4
Prognostic stratification of gliomatosis cerebri by IDH1R132H and INA expression
V. Desestret (2011)
10.1200/JCO.2008.18.0786
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
F. Di Nicolantonio (2008)
10.1111/j.1750-3639.2009.00352.x
Characterization of R132H Mutation‐specific IDH1 Antibody Binding in Brain Tumors
D. Capper (2010)
10.1002/ijc.20873
Suppression of oncogenic NRAS by RNA interference induces apoptosis of human melanoma cells
M. Eskandarpour (2005)
10.1038/sj.bjc.6606030
Targeting BRAF for patients with melanoma
H. Arkenau (2011)
10.1038/modpathol.2011.60
Metastatic colorectal cancer KRAS genotyping in routine practice: results and pitfalls
A. Lamy (2011)
10.1093/JNCI/95.6.484
Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma.
G. Singer (2003)
10.1038/SJ.JID.5700366
High frequency of BRAFV600E mutation in acquired nevi and small congenital nevi, but low frequency of mutation in medium-sized congenital nevi.
Nami Ichii-Nakato (2006)
10.1097/01.CMR.0000232300.22032.86
NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing
Esther Edlundh-Rose (2006)
10.1016/S0092-8674(04)00215-6
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
P. Wan (2004)
BRAF and KRAS mutations in colorectal hyperplastic polyps and serrated adenomas.
T. Chan (2003)



This paper is referenced by
10.1016/j.humpath.2015.12.029
BRAF and MAP2K1 mutations in Langerhans cell histiocytosis: a study of 50 cases.
K. Alayed (2016)
10.1309/AJCPFO8IIDNBIJ8Y
How molecular testing can help (and hurt) in the workup of gliomas.
K. Clark (2013)
10.1093/jscr/rjy123
Enlargement of papillary glioneuronal tumor in an adult after a follow-up period of 10 years: a case report
Yuya Fujita (2018)
10.1371/journal.pone.0198795
Development of ultra-short PCR assay to reveal BRAF V600 mutation status in Thai colorectal cancer tissues
Nunthawut Chat-Uthai (2018)
10.1177/1010428317706230
Determination of BRAF V600E (VE1) protein expression and BRAF gene mutation status in codon 600 in borderline and low-grade ovarian cancers
P. Sadlecki (2017)
10.2217/pme-2016-0023
Biopanel identifies expression status of targetable proteins in sinonasal melanoma.
Lisa Grünmüller (2016)
10.1097/NEN.0000000000000213
KIAA1549: BRAF Gene Fusion and FGFR1 Hotspot Mutations Are Prognostic Factors in Pilocytic Astrocytomas
A. Becker (2015)
10.1111/bpa.12367
Molecular Diagnostics of Gliomas Using Next Generation Sequencing of a Glioma‐Tailored Gene Panel
A. Zacher (2017)
10.1007/s10014-017-0298-4
Diencephalic pediatric low-grade glioma harboring the BRAF V600E mutation presenting with various morphologies in sequential biopsy specimens
Yukitomo Ishi (2017)
10.3390/cancers11081072
Extent of Resection, MGMT Promoter Methylation Status and Tumor Location Independently Predict Progression-Free Survival in Adult Sporadic Pilocytic Astrocytoma
C. Jungk (2019)
10.1111/his.14144
Histological features of BRAF V600E‐mutant anaplastic thyroid carcinoma
T. Chen (2020)
10.1186/2051-5960-1-20
Immunohistochemistry is highly sensitive and specific for detection of BRAF V600E mutation in pleomorphic xanthoastrocytoma
C. M. Ida (2013)
10.1016/j.anndiagpath.2020.151679
Analysis of 24 cases of epithelioid glioblastoma: Experience from a tertiary centre of North India.
Debajyoti Chatterjee (2020)
10.3892/ijo.2015.3119
Deficient mismatch repair: Read all about it (Review)
S. Richman (2015)
10.7907/F8HW-TX51.
Development of Protein-Catalyzed Capture (PCC) Agents with Application to the Specific Targeting of the E17K Point Mutation of Akt1
Kaycie M. Deyle (2014)
10.1038/ng.2868
Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas
P. Brastianos (2014)
10.1007/978-1-62703-727-3_3
Integrating molecular biomarkers into current clinical management in melanoma.
R. Kudchadkar (2014)
10.3390/cancers11060866
Validation of Immunohistochemistry for the Detection of BRAF V600E-Mutated Lung Adenocarcinomas
C. Gow (2019)
10.1016/j.prp.2012.05.008
Bone marrow biopsies of patients with hematopoietic and lymphoid disorders - epidemiology, chromosomal aberrations and molecular pathology.
Sophie Hehne (2012)
10.1002/pbc.26893
Response in a child with a BRAF V600E mutated desmoplastic infantile astrocytoma upon retreatment with vemurafenib
C. van Tilburg (2018)
Regression of BRAFV600E mutant adult glioblastoma after primary combined BRAF-MEK inhibitor targeted therapy: a report of two cases
Peter Y M Woo (2019)
10.1016/j.hpcr.2019.200302
Langerhans Cell Histiocytosis, Non-Langerhans histiocytosis and concurrent Papillary Thyroid Carcinoma with BRAF V600E mutations: A case report and literature review
Laura Wake (2019)
10.1517/13543776.2013.741593
BRAF as a therapeutic target: a patent review (2006 – 2012)
A. Zambon (2013)
10.1097/PAS.0b013e318271249e
Immunohistochemical Analysis of BRAFV600E Expression of Primary and Metastatic Melanoma and Comparison With Mutation Status and Melanocyte Differentiation Antigens of Metastatic Lesions
K. Busam (2013)
10.1007/s00428-015-1773-0
VE1 immunohistochemical detection of the BRAF V600E mutation in thyroid carcinoma: a review of its usefulness and limitations
Jong-In Na (2015)
10.1016/j.canlet.2013.01.045
Inhibition of the mitochondrial Hsp90 chaperone network: a novel, efficient treatment strategy for cancer?
M. Siegelin (2013)
10.1016/S1773-035X(15)72786-3
Intérêt de l’immunohistochimie à visée théranostique dans les carcinomes bronchiques non à petites cellules : applications et limites actuelles
Marius Ilie (2015)
10.1016/J.ANNDER.2016.09.252
L’immunohistochimie (clone VE1) est une méthode économique, spécifique et sensible pour détecter la présence d’une mutation BRAFV600E dans le mélanome
Michel Étienne (2016)
10.1007/s00401-011-0887-y
Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases
D. Capper (2011)
10.1097/PAS.0b013e31828f233d
BRAFV600E Immunohistochemistry Facilitates Universal Screening of Colorectal Cancers for Lynch Syndrome
C. Toon (2013)
10.1111/his.12537
Tumour‐infiltrating lymphocytes and expression of programmed death ligand 1 (PD‐L1) in melanoma brain metastases
A. Berghoff (2015)
10.1007/s00216-015-9204-2
Initial diagnosis of chronic myelogenous leukemia based on quantification of M-BCR status using droplet digital PCR
H. L. Lund (2015)
See more
Semantic Scholar Logo Some data provided by SemanticScholar